Clinical Trial Update: Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

View source ↗

Summary

This clinical trial extension reports long-term follow-up for subjects with chronic hepatitis C who elected retreatment with pegylated interferon and ribavirin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Chronic Hepatitis C | Status: COMPLETED